相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
Yuya Seko et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay et al.
DIABETES CARE (2018)
Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
Paul Chi Ho Lee et al.
DIABETES THERAPY (2018)
Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
Paul Chi Ho Lee et al.
DIABETES THERAPY (2018)
The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin
Akihiko Takeda et al.
INTERNAL MEDICINE (2017)
Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes
Li Tang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2017)
A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis
Chan Wah Kheong et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Effects of a Sodium-Glucose Cotransporter 2 Inhibitor in Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus: Preliminary Prospective Study Based On Serial Liver Biopsies
Norio Akuta et al.
HEPATOLOGY COMMUNICATIONS (2017)
Effect of canagliflozin on liver function tests in patients with type 2 diabetes
L. A. Leiter et al.
DIABETES & METABOLISM (2016)
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
Sunder Mudaliar et al.
DIABETES CARE (2016)
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Muhammad Abdul-Ghani et al.
DIABETES CARE (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions
Kenneth Cusi
DIABETOLOGIA (2016)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Teruo Jojima et al.
DIABETOLOGY & METABOLIC SYNDROME (2016)
Stereological Analysis of Liver Biopsy Histology Sections as a Reference Standard for Validating Non-Invasive Liver Fat Fraction Measurements by MRI
Tim G. St. Pierre et al.
PLOS ONE (2016)
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Robert J. Wong et al.
GASTROENTEROLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
Shirong Qiang et al.
DIABETOLOGY & METABOLIC SYNDROME (2015)
Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease
Wah-Kheong Chan et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
Atsuo Tahara et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Non-alcoholic fatty liver disease in diabetics - prevalence and predictive factors in a multiracial hospital clinic population in Malaysia
Wah-Kheong Chan et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2013)
The Spontaneous Course of Liver Enzymes and Its Correlation in Nonalcoholic Fatty Liver Disease
Phunchai Charatcharoenwitthaya et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani et al.
HEPATOLOGY (2012)
Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity
Giovanni Musso et al.
ANNALS OF MEDICINE (2011)
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
J. E. Gerich
DIABETIC MEDICINE (2010)
Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels
V. W-S. Wong et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline
Philip E. Cryer et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD)
M. Yoneda et al.
GUT (2007)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
The new BMI criteria for Asians by the regional office for the Western Pacific Region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers
E Anuurad et al.
JOURNAL OF OCCUPATIONAL HEALTH (2003)
分享论文
